Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 54Multiple Myeloma 45Lymphoma 44Lymphoma, Non-Hodgkin 41Leukemia 38Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Hodgkin Disease 35Myelodysplastic Syndromes 34Lymphoma, Mantle-Cell 20Lymphoma, Large B-Cell, Diffuse 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 19Leukemia, Lymphocytic, Chronic, B-Cell 16Burkitt Lymphoma 16Breast Neoplasms 13Neoplasms, Plasma Cell 11Recurrence 10Lymphoma, Follicular 10Hematologic Neoplasms 9Anemia, Refractory, with Excess of Blasts 9Lymphoma, B-Cell, Marginal Zone 8Neuroblastoma 7Myeloproliferative Disorders 7Lymphoma, Large-Cell, Immunoblastic 7Central Nervous System Neoplasms 7Blast Crisis 7Neoplasms 6Lymphoma, T-Cell 6Leukemia, Myelomonocytic, Juvenile 6Leukemia, Myelomonocytic, Chronic 6Graft vs Host Disease 6

Interventions

Rituximab 45Cyclophosphamide 34Doxorubicin 16fludarabine 14Prednisone 14Vincristine 13Etoposide 13ibrutinib 10Mycophenolic Acid 8Bortezomib 8Magnetic Resonance Spectroscopy 7Lenalidomide 7Cytarabine 7pembrolizumab 6Immunotherapy, Adoptive 6polatuzumab vedotin 5fludarabine phosphate 5Whole-Body Irradiation 5Vorinostat 5Tacrolimus 5Specimen Handling 5CT-P10 5obinutuzumab 4ibritumomab tiuxetan 4Nivolumab 4Ifosfamide 4Carmustine 4Carboplatin 4Antilymphocyte Serum 4tafasitamab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, B-Cell × Granulocyte Colony-Stimulating Factor × Clear all
NCT00482053 2018-05-14

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Stanford University

Phase 2 Terminated
3 enrolled 13 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00588094 2015-12-04

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
20 enrolled 6 charts
Lymphoid

Lymphoma, Neoplasms, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡